Connect with us
2022 Green Living Expo
The NSW Northern Rivers News
The Northern Rivers Times | NSW Northern Rivers News
2022 Green Living Expo NEWSLETTER Horizontal
The NSW Northern Rivers News
The Northern Rivers Times | NSW Northern Rivers News
previous arrow
next arrow

COVID-19 Northern Rivers News

Facilities close, services reduced to guard against COVID-19 Lismore City Council

Published

on

Federal Government’s COVID-19 Disaster Payments

Facilities close, services reduced to guard against COVID-19

In line with NSW Government-mandated lockdown across the Northern Rivers, Lismore City Council has made significant changes to its service delivery.

Residents can be assured that the following essential services will continue unaffected:

  • water supply
  • sewerage
  • waste collection
  • public safety measures.

The following facilities and services are CLOSED for the duration of the lockdown:

  • The Lismore Recycling & Recovery Centre in Wyrallah Road. Nimbin Transfer Station
  • The Revolve Shop and CDS Bulk Drop Off
  • The Goonellabah Sports and Aquatic Centre
  • The Lismore Regional Gallery
  • Lismore City Hall
  • Council depots, such as at Brunswick Street and Wyrallah Road, are closed to public access
  • All libraries in the affected Local Government Areas. However, the eLibrary is open, providing access to reading materials in downloadable digital formats from the RTRL website www.rtrl.nsw.gov.au or the Richmond Tweed Library app
  • The Corporate Centre in Oliver Avenue, Goonellabah. Some Council staff will continue to work from the building and people can continue to phone Council. Please use our on-line services at www.lismore.nsw.gov.au

Council activities that will continue to operate are:

  • Council parks and open spaces remain open, however, all play equipment, barbecues, skateparks, exercise equipment and similar are closed and cannot be used.
  •  Roadworks, with the works program continuing, subject to resources
  • The Lismore Airport, with a reduced number of flights
  • The Blakebrook Quarry
  • Lismore Cemetery and Crematorium, with some new health protocols in place
  • Internal departments such as finance, planning and development, IT and HR

Members of the public are reminded they can go online to pay rates and water bills, order and pay for conveyancing certificates and even pay invoices such as those due for development applications.

People who cannot access online services should phone the Contact Centre on 6625 0500.

Council staff are being redeployed where necessary and/or shared across the region. As part of business continuity many staff have been set up to work from home so that services can continue.

Council is committed to maintaining services wherever possible during this difficult time. The priority is the health and safety of the Lismore community and Council employees. Council thanks members of the public for their patience and understanding.

For further information on the lockdown, go to https://nnswlhd.health.nsw.gov.au/

Continue Reading

COVID-19 Northern Rivers News

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC residents

Published

on

By

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC resident

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC residents

Australia has just passed two million official Covid cases today (Thursday), with one-in-10 New South Wales and Victorian residents now living with a diagnosis leading into the upcoming Federal Election, the latest VaxEnomicTM Forecaster from C-suite strategy group Provocate reveals.

Provocate Managing Director Troy Bilsborough said it represented a doubling of cases in under two weeks since Provocate first revealed Australia had hit the one-million case mark last Monday (10 January 2022).

“It took Australia two years to reach its first one million Covid cases and under two weeks to reach its second,” said Mr Bilsborough – a former senior advisor to Federal Health, Aged Care and Child Care Ministers.

“Healthcare influenced more votes than any other issue at the last Federal election and two million Australians now living with a Covid diagnosis will likely entrench that.

“This week’s negative polling on the Federal Government’s handling of the pandemic and economy continues to support our prediction that Covid and health will likely sway votes – and even the result – at May’s election.

“The arrival of a heavily-mutated variant like Omicron within five months of Delta also means there’s every chance Australia could be facing another outbreak from another new variant heading into the Federal Election campaign.”

“However, the biggest threat to business and voter confidence is not the virus itself, but politically-opposed state and Federal governments making decisions based on electionomics, not epidemiology or the economy.

It comes as top US Government Covid adviser Anthony Fauci also warned on Tuesday Omicron may not be the end of Covid with further mutations possible, supporting Provocate’s recent prediction Australia could be facing another virus variant in time for the next Federal election, slated for May 2022.

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC resident

AUS passes 2m Covid cases, hits 1-in-10 NSW & VIC resident

“The big unknown is whether Covid continues to matter when Australia is predicted to go to the polls in May – and whether opposition parties can continue to maintain voter dissatisfaction for that long.

“Much of this will hinge on how the longer-term impacts of Covid for the millions of Australians who now caught the virus, and how much onus attention medical, patient and worker representations place on having them recognised as chronic illness.”

About 90 per cent of total Australian cases have been recorded in the seven weeks since Omicron’s arrival in late November. That equates to an 800%+ increase in recorded cases in less than seven weeks, noting actual infections in the community were likely double or more that due to restricted testing options.

Provocate last week predicted the rapid transition from Covid as a public health and economic threat to a personal problem for millions of Australians would negatively impact voter views towards the Federal Government leading into the Election.

This was supported by this week’s Resolve Political Monitor, which showed since the May 2021 Federal Budget:

· a -22 point decline in the Federal Government’s lead on handling of Covid and the pandemic.

· a -13 point decline in the Federal Government’s lead on handling of economic management.

· a -10 point decline in the Federal Government’s lead on handling of health & aged care, with the Opposition now in front.

· a -5 point decline in the Federal Government’s primary vote, with the Opposition taking the lead for the first time during that period.

· A -16 point decline in the Federal Government’s lead on Preferred Prime Minister.

 

Figure 1 Source: Provocate analysis of ANU 'The 2019 Election Study'

Figure 1 Source: Provocate analysis of ANU ‘The 2019 Election Study’

Continue Reading

COVID-19 Northern Rivers News

TGA Approves Pfizer’s Novel COVID-19 Oral Treatment in Australia

Published

on

By

The NSW Northern Rivers Times COVID19 News Updates

TGA Approves Pfizer’s Novel COVID-19 Oral Treatment in Australia

• Therapeutic Goods Administration (TGA) approves PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for supply to Australia.

• PAXLOVID is the first oral treatment of its kind; it includes nirmatrelvir, a 3CL (or main) protease inhibitor that was specifically designed to combat SARS-CoV-2.

• Pfizer Australia has entered an agreement with the Australian Government to supply 500,000 treatment courses over 2022.

SYDNEY, AUSTRALIA, 20 January 2021 – Pfizer announced today that Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval for the supply and use in Australia of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets. PAXLOVID has provisional approval for the treatment of coronavirus disease 2019 (COVID-19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.

PAXLOVID is the first oral antiviral of its kind; it includes nirmatrelvir, a 3CL protease (also known as Main protease or Mpro) inhibitor that was specifically developed in Pfizer’s laboratories to combat SARS-CoV-2. Under this authorisation, PAXLOVID can be prescribed as an oral treatment to certain high-risk adults within the first 5 days of symptomatic infection, potentially helping patients avoid severe illness which can lead to hospitalisation or death.

“This milestone in Australia is an important moment in our continued fight against COVID-19, paving the way for use of PAXLOVID as cases continue to rise and we address the threat of a new variant of concern, Omicron,” said Anne Harris, Pfizer Australia and New Zealand Managing Director. “This at-oral therapy, developed to reduce hospitalisations and save lives, has the potential to transform COVID-19 treatment and help lessen the devastating impact of the virus that has now taken over 5 million lives globally”, Ms Harris said.

The TGA based its decision on positive results from the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) interim analysis, which enrolled non-hospitalised adults with confirmed COVID-19 who were at increased risk of progressing to severe illness. The data demonstrated an 89% reduction in risk of COVID-19-related hospitalisation or death from any cause in adults treated with PAXLOVID compared to placebo in those treated within three days of symptom onset, with no deaths in the treatment group. Similar results were seen in those treated within five days of symptom onset. Treatment-emergent adverse events were comparable between PAXLOVID (19%) and placebo (21%), most of which were mild in intensity. Pfizer recently announced that results from the final analysis of the primary endpoint from all patients enrolled in EPIC-HR were consistent with the interim analysis, confirming efficacy with a similar safety profile. Additional Phase 2/3 clinical trials are ongoing in adults at standard risk of progressing to severe illness, and in those who have been exposed to the virus through household contacts.

In October 2021, Pfizer announced an agreement with the Australian Government to supply 500,000 treatment courses of PAXLOVID over 2022. With the oral treatment now approved for supply and use by the TGA, Pfizer will begin delivering the first treatment courses from Q1 2022.

Continue Reading

COVID-19 Northern Rivers News

Under 12s to access protection against the worst of COVID from Monday 10 January

Published

on

By

Under 12s to access protection against the worst of COVID from Monday 10 January

Under 12s to access protection against the worst of COVID from Monday 10 January

• Pfizer vaccine available from Monday 10 January to children aged 5 to 11 years.
• Parents and guardians are encouraged to book through the Vaccine Clinic Finder.
• Vaccination protects our younger community members from the worst of COVID.
Children aged 5 to 11 in the North Coast region will be eligible to receive a new, lower-dose formulation of Pfizer’s COVID-19 vaccine from Monday 10 January 2022.
With the dramatic increase in transmission rates due to the now-dominant Omicron strain, Healthy North Coast Chief Executive Officer Julie Sturgess is strongly encouraging parents and guardians to make a booking for children in their care in the coming weeks.
‘We know that vaccination reduces the risk of transmission as well as serious illness and hospitalisation from COVID-19,’ said Ms Sturgess.
‘The North Coast community vaccination rate for those aged 16 and up now stands at 93.6%, and our 12 to 15 year-olds have been eligible to book their COVID vaccination since September 2021.
‘With the strong uptake in our region, we expect that parents and carers are well acquainted with the benefits of vaccination and are ready to extend the same level of protection to our younger community members,’ Ms Sturgess said.
The Australian Technical Advisory Group on Immunisation (ATAGI) recommended vaccination for children aged 5 to 11 years in December 2021, following earlier approval by the Therapeutic Goods Administration.
Approval was based on a careful evaluation of available data to support its safety and efficacy among this age group.
The under-12s Pfizer vaccine is 10μg (0.2mL) or only a third of the recommended 30μg dose administered to people aged 12 and over.
The smaller dose will have an orange-capped vial to differentiate it from the 12 years and older vaccine.
Children under 12 will still receive two doses, though these will be eight weeks apart, unlike the three-week interval for older cohorts.
Health advice is that a longer interval between doses appears to generate a stronger immune response.
‘We’re encouraging any parent or guardian to use the Vaccine Clinic Finder to book an appointment over the coming weeks, while their school-aged children are still on holidays,’ Ms Sturgess said.
‘If you are unable to find a suitable appointment, please check back regularly as more appointments will become available as supply to the region increases.
‘Healthy North Coast is also open to working with other appropriate venues and locations, which may include schools, to expedite the rollout.’
Any parent of guardian who has concerns about the suitability of the vaccination for a child in their care should speak with their GP.

Continue Reading

Latest News

Subscribe for our newsletter!

error: Alert: Content is protected !!